Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.45 USD
-0.15 (-4.17%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $3.41 -0.04 (-1.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
PRLD 3.45 -0.15(-4.17%)
Will PRLD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRLD
New Strong Buy Stocks for January 25th
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
PRLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
Other News for PRLD
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
Buy/Sell: Wall Street's top 10 stock calls this week
Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls
Prelude Therapeutics just downgraded at Barclays, here's why
Barclays cuts Prelude to underweight, cites lack of near-term catalysts